



## LITERATURE REVIEW

# Diagnosis and management of acute rheumatic fever

Irma Kartikasari<sup>1,2\*</sup>, Syafarinah Nur Hidayah Akil<sup>1</sup>

1) Faculty of Medicine, Universitas Muhammadiyah Surabaya, Indonesia

2) Department of Cardiology and Vascular Medicine, RSUD Dr. Soegiri Lamongan, Indonesia

### ARTICLE INFO

*Submitted* : 15<sup>th</sup> June 2022

*Accepted* : 20<sup>th</sup> July 2023

*Published* : 27<sup>th</sup> July 2023

#### **Keywords:**

acute rheumatic fever, rheumatic heart disease, GAS pharyngitis

#### **\*Correspondence:**

[irma.cardio@gmail.com](mailto:irma.cardio@gmail.com)

*This is an Open access article under the CC-BY license*



### ABSTRACT

Acute rheumatic fever is a non-suppurative, immune-mediated consequence of group A streptococcal pharyngitis. Recurrent or severe acute rheumatic fever can cause permanent cardiac valve damage and rheumatic heart disease. Universally, the most common major manifestations during the first episode of ARF remain carditis and arthritis. Subclinical carditis now can fulfill a major criterion for ARF in all populations as in revised Jones criteria – AHA 2015. Many of the clinical features of ARF are non-specific, so a wide range of differential diagnoses should be considered. Primary prevention requires accurate recognition and proper antibiotic treatment of GAS pharyngitis. Prevention of recurrent attacks of rheumatic fever (secondary prevention) is the most cost-effective way of preventing further rheumatic heart disease (RHD). Penicillin remains the antibiotic of choice. Intramuscular penicillin is preferred as it is more effective than oral penicillin and results in better compliance.



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



### INTRODUCTION

Acute rheumatic fever (ARF) is a non-suppurative complication following infection by *Streptococcus pyogenes*, or group A  $\beta$ -hemolytic streptococcal (GAS) in the tonsil and pharynx. This disease can cause joint, skin, subcutaneous tissue, brain, and heart symptoms. Damage to the heart valve tissue, otherwise known as rheumatic heart disease (RHD), can become a chronic condition that can result in congestive heart failure, stroke, endocarditis, and death (Carapetis et al., 2005; Cilliers, 2006; Kumar & Tandon, 2013; Seckeler & Hoke, 2011; WHO, 2004).

The incidence and prevalence of ARF and RHD have decreased in developed countries since the early 1900s. Still, these diseases remain a significant cause of morbidity and mortality among young people in developing countries. The condition is estimated to occur in up to 30 million children and young adults, and each year an estimated 90,000 people die from this disease (Kumar & Tandon, 2013). The pathophysiology and immune response underlying ARF occurrence is still not adequately understood. Clinical manifestations and disease severity in patients are influenced by host susceptibility, the virulence of the infecting organism, and favorable environmental factors (Cilliers, 2006; Kaplan, 2005).

Establishing a precise and accurate diagnosis of ARF is very important to avoid over or underdiagnosis that can harm the patient. In general, the diagnosis of ARF is established based on clinical manifestations and supported by laboratory tests. More than 50 years ago, T. Duckett Jones established criteria to help diagnose ARF. These criteria have been revised by the American Heart Association (AHA) (Kumar et al., 2020). Changes made include considering the differences in clinical

manifestations in the high-risk population and using echocardiography/Doppler to assess the presence of subclinical carditis. The AHA's recent revision of the Jones criteria is now considered closer to some of the other international guidelines (Gewitz et al., 2015).

Clinicians must be more vigilant in assessing the comprehensive differential diagnosis of the clinical manifestations of ARF, especially in carditis, arthritis, and chorea so that patients can receive appropriate management. Therefore, this review aims to describe comprehensively the disease, from the diagnosis to the treatment and prevention.

### LITERATURE REVIEW

#### Epidemiology of Acute Rheumatic Fever

The incidence and prevalence of ARF and RHD began to decline in developing countries in the second half of the 19th century, and this decline was influenced by more hygienic environmental conditions and reduced population density. The advent of antibiotics in the 1950s also accelerated this decline. Nonetheless, ARF and RHD remain the leading causes of morbidity and mortality at a young age in many developing countries (Auala et al., 2022; Seckeler & Hoke, 2011). The World Health Organization (WHO) states that approximately 0.5 million individuals experience ARF each year, most of which occur in developing countries, where ARF is said to exceed 50 cases per 100,000 children. Epidemiological data from many developing countries are still lacking, and the data currently obtained may still be far below the actual number (WHO, 2004). The latest data regarding the prevalence of rheumatic fever in Indonesia for the years 1981 - 1990 found 0.3-0.8 among 1000 school children, much lower than in other developing countries (Madiyono, 1998). Much higher rates of 80-100 cases per 100,000 have been documented in several



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



carefully conducted studies in Indigenous populations of Australia and New Zealand (Sudeep & Sredhar, 2013).

ARF is a disease that can be found in children and young adults. ARF most often occurs in children aged 5-14 years. The first ARF attack is rarely found in children under 5 years of age. The incidence decreases from the age of 15 years and over. The first ARF attack is sporadic at 35 years and over (Seckeler & Hoke, 2011). Relapses of ARF are common in adolescents and young adults. Relapses of ARF are rarely diagnosed in adults aged 45 years and over. No data indicate a difference in the incidence of ARF between men and women (Kaplan, 2005; WHO, 2004).

The highest prevalence of RHD is in the age range of 20-50 years. In several studies stating that the prevalence of RHD was higher in groups of women living in poor and developing countries, researchers linked it to several reasons, including genetic and social factors. There are estimated to be more than 15 million cases of RHD worldwide, with 282.000 new patients and 233.000 deaths yearly. Subsequent data from studies in Asia show that children with RHD can reach 1.96-2.21 million individuals. In studies in Asian countries, the burden of RHD was estimated at 10.8-15.9 million individuals, and estimates of RHD in Asian countries show that the global burden is significantly higher than previous estimates for children and all age groups. RHD mortality in Asian countries in a study is said to be 3.3 percent per year or around 356,000 - 524,000 deaths/year (Carapetis et al., 2005; Kumar et al., 2020; Sudeep & Sredhar, 2013).

The number of cases of RHD in Indonesia was over 1 million in 2015 (Watkins et al., 2017). There were several studies on the incidence of RHD conducted in various regions of Indonesia, from South Sumatra, Central Jakarta, East Java,

and South Sulawesi (Choironi et al., 2022; Desita et al., 2021; Rudiktyo et al., 2022; Syam et al., 2020). The number of cases was plenty, reaching 57,4% of the total rheumatic disease in a particular region. There were around 50 to 80 new cases in an area found in children from 2005 to 2009. The cases were higher in the cardiac center in Jakarta, where there are almost 300 new cases of RHD (Syam et al., 2020). The mortality rate in Indonesia is nearly 5 per 100.000 population at risk, which is higher than other infective diseases (Arafuri et al., 2022).

### Pathophysiology of Acute Rheumatic Fever

Although ARF has been known for over 150 years, a clear understanding of the pathophysiology is still unknown. The infectious role of GAS as an initial event is recognized. It is supported by the occurrence of ARF outbreaks following pharyngitis outbreaks, as well as evidence of elevated antistreptococcal antibodies (ASO) in patients with ARF (Cilliers, 2006; Gewitz et al., 2015; Kaplan, 2005; Kumar et al., 2020; Seckeler & Hoke, 2011).

There are currently three main theoretical hypotheses that have been advanced over the last five decades to explain the streptococcal pathogenesis of ARF. The hypotheses include: (1) direct infection (e.g., infection from GAS); (2) the effect of streptococcal toxins (streptolysin O is the most frequently discussed); and (3) the concept of antigenic mimicry or molecular mimicry associated with an abnormal immune response, a hypothesis that is currently more widely accepted (Carapetis et al., 2005; Kaplan, 2005).

The clinical manifestations of the response and the severity of the disease in an individual are determined by the host's susceptibility, the infecting organism's virulence, and the conducive environment. The theory of molecular



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



mimicry states that antibodies directed against GAS cross-react with tissues in the host. In brief, it appears that a combination of both humoral and cell-mediated immune responses occurs against bacterial antigens, which then cross-react with human tissues, such as those of the heart, joints, skin, and central nervous system, through molecular mimicry. The exact mechanism of initiation of the damage is still unclear. Some damage appears to be due to the infiltration of macrophages and T cells that persists for years after the initial event (Auala et al., 2022; Kaplan, 2005).

Not all individuals are susceptible to ARF, and not all GAS strains are capable of causing ARF in susceptible individuals. Approximately 3-5% of individuals from each population are estimated to have a susceptibility to the occurrence of ARF, although until now, the individual susceptibility factors are not known with certainty. It is now known that only a few GAS strains are 'rheumatogenic'. The potential for rheumatogenicity is thought to be determined by the M protein or the antiphagocytic components of the bacterial cell wall (Cunningham, 2000; Woldu & Bloomfield, 2016). M protein is the main virulence factor of Streptococcus and has an essential role in the pathogenesis of ARF and RHD. When an individual is infected with a rheumatogenic GAS strain, there is a latency period of approximately three weeks before symptoms of ARF appear. By the time ARF symptoms appear, the infecting GAS has already been eradicated from the host by the existing immune response (Arabaci & Ak, 2020; Brouwer et al., 2023).

### Diagnosis of Acute Rheumatic Fever

The diagnosis of ARF presents clinical challenges for clinicians. Accurate diagnosis is critical. If it is overdiagnosed, the patient will receive unnecessary treatment for a long

time. On the contrary, if it is underdiagnosed, ARF will lead to further attacks, causing heart damage and premature death. The diagnosis of ARF remains a clinical decision because, to date, there are no specific laboratory tests (Ralph et al., 2020).

The Jones criteria have guided clinicians in diagnosing ARF since 1944. Over time the Jones criteria have been modified by the American Heart Association (AHA) in 1992, then reconfirmed at the AHA-sponsored workshop in 2000. Finally, the AHA issued the latest revision through the AHA Scientific Statement in 2015 (Gewitz et al., 2015). The current modifications bring the Jones criteria into line with other international guidelines for the diagnosis of ARF by defining high-risk populations and recognizing the differences in clinical presentation in high-risk populations, including the use of Doppler echocardiography as a tool for diagnosing the presence of cardiac involvement (**Table 1**) (Kumar et al., 2020; Reményi et al., 2012).


Individuals are at low risk for ARF if they come from a population with a low incidence of ARF or RHD. Where good epidemiological data are available, a low-risk population is defined as an area that has an incidence of ARF  $\leq 2$  per 100,000 school-age children (aged 5-14 years) per year or an all-age prevalence of PJR  $\leq 1$  per 1000 population per year (Seckler & Hoke, 2011). Depending on their reference population, children of unknown origin from a low-risk population are considered moderate to high risk (Gewitz et al., 2015).

Evidence of a previous GAS infection is critical in diagnosing ARF. All major clinical manifestations listed in the Jones criteria must be accompanied by evidence of a disease from GAS. The clinical manifestations of chorea and indolent carditis did not require evidence of previous GAS infection (**Figure 1**). The



Table 1. Revised Jones criteria (AHA-2015 from (Gewitz et al., 2015)

<b>a. For all patient populations with evidence of previously GAS infection</b>	
<b>Diagnosis: initial ARF</b>	2 major criteria or 1 major + 2 minor
<b>Diagnosis: recurrent ARF</b>	2 major criteria or 1 major + 2 minor or 3 minor criteria
<b>b. Major criteria</b>	
<b>Low risk population</b>	<b>Moderate or high risk population</b>
<ul style="list-style-type: none"> <li>• Carditis (clinical and/or subclinical)</li> <li>• Arthritis (only polyarthritis)</li> <li>• Chorea</li> <li>• Erythema marginatum</li> <li>• Subcutaneous nodules</li> </ul>	<ul style="list-style-type: none"> <li>• Carditis (clinical and/or subclinical)</li> <li>• Arthritis (monoarthritis/polyarthritis, polyarthralgia)</li> <li>• Chorea</li> <li>• Erythema marginatum</li> <li>• Subcutaneous nodules</li> </ul>
<b>c. Minor criteria</b>	
<b>Low risk population</b>	<b>High risk population</b>
<ul style="list-style-type: none"> <li>• Polyarthralgia</li> <li>• Fever (<math>\geq 38.5^{\circ}\text{C}</math>)</li> <li>• ESR <math>\geq 60\text{mm}</math> in first hour and/or CRP <math>\geq 3.0 \text{ mg/dL}</math></li> <li>• PR interval lengthening, after accounting for age variability (unless carditis is the major criterion)</li> </ul>	<ul style="list-style-type: none"> <li>• Monoarthralgia</li> <li>• Fever (<math>\geq 38^{\circ}\text{C}</math>)</li> <li>• ESR <math>\geq 30\text{mm}</math> in first hour and/or CRP <math>\geq 3.0 \text{ mg/dL}</math></li> <li>• PR interval lengthening, after accounting for age variability (unless carditis is the major criterion)</li> </ul>



B, C, and D require evidence of GAS infection.

Figure 1. Strategy for diagnosing ARF (Gewitz et al., 2015)



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



2015 AHA states that if one of the following statements is obtained, it can be used as evidence that a GAS infection has previously occurred: (1) An increase or increase in the titer of anti-streptolysin O (ASO) or other streptococcal antibodies (anti-DNase B) (Class I; Level of Evidence B), the presence of a rise in titer is better evidence than a single titer result; (2) Positive throat culture results for GAS (Class I; Level of Evidence B); and (3) A positive carbohydrate antigen rapid test or rapid antigen detection test (RADT) GAS result in a child who has a clinical presentation strongly supports the presence of streptococcal pharyngitis (Class I; Level of Evidence B)<sup>7</sup>.

ARF can be found in patients when the first attack (initial) occurs or during repeated attacks (recurrent). The diagnosis of ARF in the first attack is upright when 2 major criteria are met or 1 major criterion with 2 minor criteria. In contrast, for ARF relapse, the requirements must be met are the same as the

criteria for first-attack ARF, or if major criteria are not found, at least 3 minor criteria must be met.

Under certain conditions, clinicians sometimes encounter cases with clinical presentations that do not meet Jones' criteria but have strong reasons to suspect ARF as the most likely diagnosis. This is likely to occur in areas with a high incidence of ARF, and regions where tests to confirm GAS infection are not yet available. Such patients can be categorized as "Probable" ARF (Possible Rheumatic Fever). In these circumstances, consideration of secondary prophylactic antibiotics for 12 months, followed by repeated evaluations, including a careful history, physical examination, and periodic echocardiography, may be performed (Class IIa; Level of Evidence C). WHO also has diagnostic criteria for ARF and RHD based on the Jones criteria; it is said that WHO has made diagnostic criteria that focus more on sensitivity than specificity (**Table 2**).

**Table 2.** Criteria for Diagnosis of ARF and RHD (WHO, 2004, 2020)

Diagnostic category	Criteria
<b>First attack of rheumatic fever</b>	Two majors or one major and two minor plus evidence of infection <i>Streptococcus beta hemolyticus</i> group A previously
<b>Recurrent attacks of rheumatic fever without RHD</b>	Two majors or one major and two minor plus evidence of infection <i>Streptococcus beta hemolyticus</i> group A previously
<b>Recurrent attacks of rheumatic fever with RHD</b>	Two minors plus proof <i>Streptococcus beta hemolyticus</i> infection Group A before
<b>Rheumatic Chorea</b>	No other major criteria are required or evidence of beta <i>Streptococcus</i> infection hemolyticus group A
<b>RHD (pure or combined mitral stenosis with mitral insufficiency and/or aortic valve disorders)</b>	No other criteria are needed for diagnosed as PJR



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



### Clinical Manifestations of Acute Rheumatic Fever

Clinical manifestations in ARF can be divided into 2 groups: clinical manifestations that meet major and minor criteria. The most common major clinical manifestations encountered during the first attack were carditis (50-70%) and arthritis (35-66%), followed by chorea (10-30%), then subcutaneous nodules (10%), and erythema marginatum (<6%), which are the least common, but highly specific for ARF (Reményi et al., 2012; WHO, 2004, 2020). Minor clinical manifestations include joint pain, fever, increased C-reactive protein value and sedimentation rate, and ECG features in a prolonged PR interval. Because these signs and symptoms are common in many diseases, they are less valuable than the minor clinical manifestations on the Jones criteria. Having a family history of ARF can also increase suspicion of this disease.

#### *Carditis*

Pathophysiologically, the endocardium, myocardium, and pericardium can all be affected, but rheumatic carditis is almost always associated with valvulitis of the mitral and aortic valves. Therefore, the presence of myocarditis and/or pericarditis alone, without a valvulitis, is not sufficiently strong to be considered rheumatic carditis, and other etiologies must be considered (Cilliers, 2006; Kaplan, 2005; WHO, 2004).

Carditis can be divided into clinical and subclinical. Clinical carditis may be recognized by an apical holosystolic murmur of mitral regurgitation (with or without an apical mid-diastolic murmur, Carey Coombs). Aortic regurgitation is less common and is characterized by an early diastole murmur at the heart base. In individuals with a previous history of RHD, a change in the character of any pre-existing murmur or the presence of a significant new murmur suggests the presence

of carditis (Cilliers, 2006; Gewitz et al., 2015; Kaplan, 2005). Subclinical carditis refers exclusively to conditions in which the clinician does not recognize the classic auscultatory finding of valve dysfunction. Still, echocardiography/Doppler examination provides evidence of mitral or aortic valvulitis. The echocardiographic features of valvulitis were made based on specific recommendations for pathological MR/AR. Morphological criteria on echocardiographic examination are also crucial for diagnosing and course ARF and RHD (Ralph et al., 2020; Reményi et al., 2012).

#### *Arthritis*

Arthritis is defined as swelling of the joints, followed by two or more of the following: limitation of movement, heat in the joints, and joint pain. Usually, arthritis in ARF is very painful. It often affects the large joints, especially the knees and ankles. Polyarthritis that occurs is generally asymmetrical and migratory (migratory polyarthritis), one joint becomes inflamed while another begins to decrease, but several joints can also become progressively inflamed simultaneously. In addition, arthritis in ARF responds well to salicylates or non-steroidal anti-inflammatory drugs and usually improves within 3 days of therapy. In general, arthritis in ARF is a symptom that can improve on its own, even without therapy, lasting for approximately 4 weeks. Arthritis in ARF does not result in long-term joint deformity. Arthritis involving only one joint (monoarthritis) is currently a major criterion in the high-risk population for ARF (Gewitz et al., 2015; WHO, 2020).

#### *Polyarthralgia*

Polyarthralgia is classified as a minor clinical manifestation according to the revised Jones Criteria AHA-2015. Polyarthralgia as a major manifestation occurs only in moderate or



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



high-risk populations and only after careful consideration, and other causes of arthralgia, such as autoimmune, viral, or reactive arthropathies, have been excluded (Class IIb; Level of Evidence C). Polyarthralgia in ARF has the same characteristics as polyarthritis in ARF, which is asymmetric, mobile, and affects large joints. If polyarthritis has been found as a major clinical manifestation of ARF, then polyarthralgia cannot be counted as a minor criterion (Gewitz et al., 2015; Ralph et al., 2020; WHO, 2020).

### *Chorea (Sydenham Chorea)*

Chorea may appear with other manifestations of ARF but may also be the only clinical manifestation. Chorea is a neurological disorder characterized by rapid, aimless involuntary movements (often of the hands, feet, tongue, and face) associated with muscle weakness and emotional lability. Movements that arise are not directed and not repetitive but occur suddenly and erratically. These movements disappear during sleep. Most patients with chorea will show improvement in symptoms within a few weeks, and almost all patients within six months. In rare cases, the chorea may persist for 2-3 years (Gerber et al., 2009; Gewitz et al., 2015; Ralph et al., 2020).

Chorea can occur only on one side (hemichorea) and is more common in girls, especially not always in their teens. Signs that can be used to recognize chorea include: (1) "Milkmaid's grip" (rhythmic squeezing movement when the patient is asked to hold the examiner's finger); (2) "Spoonng" (movement of wrist flexion and extension of the fingers when the hand is straightened); (3) "Pronator sign" (rotating movement of the arms and palms outwards, when the hands are held above the head); and (4) Inability to maintain when asked to stick out the tongue. Chorea can occur after a prolonged latency period after GAS infection;

therefore, chorea can be the sole criterion for diagnosing ARF without other manifestations, and there is no need for evidence of having been infected with GAS. Chorea is strongly associated with carditis, so echocardiographic evaluation is essential, even if a heart murmur is not found (Gewitz et al., 2015; Ralph et al., 2020).

### *Subcutaneous Nodules*

Subcutaneous nodules generally appear 1-2 weeks after the appearance of other clinical manifestations and last only 1-2 weeks (rarely more than one month). This condition is often found in patients with carditis. These are usually firm, painless nodules; the overlying skin is not inflamed and varies in size from a few millimeters to several centimeters. The most common location is over the surface of bone or tendons. It is best detected by actively palpating for these nodules, especially in the elbows, wrists, knees, nape, and spinous processes of the vertebrae {Citation}.


### *Erythema marginatum*

Erythema marginatum is a unique pink rash that appears pale in the center and has a rounded, wavy border. The rash usually appears on the trunk and upper extremities and rarely affects the face. Heat can trigger the appearance of this rash, and the rash turns pale when pressed. Like other rashes, erythema marginatum may be more challenging to detect in dark-skinned individuals (Gerber et al., 2009; Gewitz et al., 2015; Ralph et al., 2020).

### **Differential Diagnosis of ARF**

Knowing and considering the differential diagnosis of each major clinical manifestation of ARF is very important in making a precise and accurate diagnosis. **Figure 2** lists alternative diagnoses when evaluating patients with arthritis, carditis, or chorea (modified from Australian and New Zealand guidelines).





**Figure 2.** Differential Diagnosis in Arthritis, Carditis, and Chorea (Source: Gewitz et al., 2015)

Subclinical carditis at this time can be a major criterion for ARF by passing strict criteria on echocardiographic examination alone without the need for clinical findings; this requires knowledge of caution against other findings that can resemble rheumatic carditis so that overdiagnosis does not occur, especially in at-risk populations. Three of the four criteria used to diagnose pathological mitral valve regurgitation or aortic valve regurgitation (jet length, velocity, and completeness of the Doppler envelope) are affected by systemic blood pressure and,

therefore, the circulating loading conditions at the time of echocardiographic examination should also be considered (Gewitz et al., 2015; Ralph et al., 2020; Reményi et al., 2012).

### Supporting Examination on ARF

In individuals suspected of having ARF, the supporting examinations that must be carried out include laboratory examinations, ECG, chest X-rays, and echocardiography (Ralph et al., 2020). The examinations that should be done in diagnosing ARF can be seen in **Table 3.**



**Table 3.** Supporting Examination in Suspected Patients with ARF

Recommendations in All Cases	Tests for Alternative Diagnostics, Depending on Clinical Findings
<ul style="list-style-type: none"> <li>• Blood sedimentation rate (repeated weekly since ARF diagnosis confirmed)</li> <li>• C-reactive protein</li> <li>• Blood culture if fever</li> <li>• Electrocardiography (repeated as needed if the conduction abnormality is more than first degree)</li> <li>• Chest photo, clinically and echocardiography showed carditis</li> <li>• Echocardiography (repeated as needed in 2-4 weeks if equivocal or serious carditis)</li> <li>• Throat smear culture (preferably before antibiotics)-GAS culture</li> </ul>	<ul style="list-style-type: none"> <li>• Serological tests for reactive arthritis</li> <li>• Anti Nuclear Antibody (ANA) for autoimmune arthritis</li> <li>• Repeat blood culture if endocarditis or septic arthritis is suspected</li> <li>• X-rays of joints</li> <li>• Copper, caeruloplasmin, anti-nuclear antibody, drug screen, and head CT/MRI considerations for choreiform movements</li> </ul>

**Management of ARF**

In the acute phase, medical management of patients with acute rheumatic fever is divided into four parts, namely: 1) management for group A streptococcus, although it does not improve the prognosis within 1 year but can prevent the spread of rheumatogenic strains; 2) general management for acute episodes; 3) heart failure caused by carditis is treated according to heart failure therapy, with monitoring of the possibility of arrhythmias; and 4) administration of prophylactic antibiotics (secondary prevention), the choice of therapy with penicillin, except in patients who are allergic to penicillin (Cilliers, 2006; Kumar et al., 2020; Ralph et al., 2020).

The management for acute episodes, including anti-inflammatory drugs, is used to control arthritis, fever, and other acute symptoms. Salicylates are the recommended drug, and steroids are only used if it doesn't work with the administration of salicylates. Bed rest is recommended, especially in patients with

carditis. Valproic acid and carbamazepine are now preferred over haloperidol as anti-chorea. Medical administration is only carried out if chorea significantly interferes with daily activities, endangers oneself and those around them, or the patient, family, and friends cannot deal with this condition; a calm environment and reduced stress can reduce symptoms (Ralph et al., 2020).

**Prevention of Acute Rheumatic Fever**

*Primordial Prevention*

Primordial prevention consists of improving the socio-economic status of the community, preventing overcrowding, improving nutritional quality, ensuring the availability of good medical care, and educating the public about the risk of ARF after getting a throat infection, especially in children under 15 years of age (Kumar et al., 2020).

*Primary Prevention*

Primary prevention of ARF is carried out by properly identifying and administering



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



appropriate antibiotics for GAS tonsillopharyngitis. The diagnosis of GAS pharyngitis is best made by combining clinical judgment and the results of diagnostic tests. The standard criterion for GAS infection is the examination of a throat swab culture. Appropriate administration of antibiotics to patients with throat infections who have symptoms suggestive of GAS infection (pharyngeal exudate and enlarged cervical lymph nodes) can reduce the risk of ARF by 70% (Cilliers, 2006; Gerber et al., 2009; Gewitz et al., 2015; Kaplan, 2005).

The antibiotics recommended for treating GAS are intramuscular benzathine penicillin G and oral penicillin V, except in individuals with a history of penicillin allergy. Until now, GAS which is resistant to penicillin, has never been found. Patients who have received this antibiotic therapy 24 hours later can be considered no longer contagious. Erythromycin may be considered in patients on beta-lactam drugs but have a higher risk of gastrointestinal side effects than other drugs (Class IIb, Level of Evidence B). In addition, there is evidence that several strains of GAS are resistant to erythromycin in several countries worldwide, resulting in therapeutic failure. In recent years, macrolide resistance rates in pharyngeal bacteria in most parts of the United States have been 5% to 8% (Gerber et al., 2009).

### **Secondary Prevention**

The most effective strategy for lowering morbidity and death in underdeveloped nations is secondary prevention. Adopting echocardiography criteria for diagnosis and follow-up would boost adherence to secondary prevention because there are between 3 and 10 cases of subclinical RHD for every case of clinically diagnosed RHD (Barik, 2018; Katzenellenbogen et al., 2017). In mild RHD, prophylaxis is necessary for at least five years

after RHD diagnosis or until age 21 (whichever is longer) if there is no history of ARF and the patient is under 35 years old. In moderate RHD, prophylaxis is necessary for at least five years after RHD diagnosis or until age 35 (whichever is longer) if there is no history of ARF and the patient is younger than 35. When RHD is severe, prophylaxis is necessary for at least five years after diagnosis or until age 40 (whichever comes first) if there is no known history of ARF (Ralph et al., 2020).

It is known that individuals who have had previous ARF, in which GAS pharyngitis develops, are at increased risk for recurrent attacks of ARF. Repeated attacks may result in a worsening of PJR that developed after the first attack or occasionally may result in a new onset of PJR in a patient who did not have cardiac manifestations during the first attack. GAS infection does not need to cause symptoms to trigger a relapse of ARF. In addition, ARF relapses can also occur even when signs of GAS infection are treated optimally. Therefore, prevention of recurrent ARF (secondary prevention) requires continuous administration of prophylactic antibiotics. The recommended duration of prophylactic antibiotics for secondary prevention varies based on the clinical manifestations (Al-Jazairi et al., 2017; Gerber et al., 2009; Ralph et al., 2020).

Intramuscular administration of benzathine penicillin G is superior to oral penicillin in preventing ARF relapses. It is given every four weeks or can be every three weeks in patients who are proven to have had ARF relapses. There is strong evidence that secondary prevention can reduce the severity of RHD by inhibiting disease progression. The benefits of long-term intramuscular administration of benzathine penicillin G outweigh the risks of penicillin allergy, which is very rare. Available data indicate that the rate of allergic and anaphylactic reactions to intramuscular



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



administration of benzathine penicillin G each month is 3.2% and 0.2%. Fatal allergic reactions are said to be very rare. The success of prophylactic oral antibiotics is highly dependent on patient compliance. Secondary prevention with oral therapy is more suitable for patients with a low risk of recurrent ARF (Cilliers, 2006; Gewitz et al., 2015; Kaplan, 2005; Ralph et al., 2020).

### Tertiary Prevention

The therapy of RHD's side effects, such as stroke, infective endocarditis, and arrhythmia, as well as the medical management of heart failure and the surgical management of valve defects, are all considered tertiary therapies (Maryland, 2020).

### CONCLUSION

Acute rheumatic fever is a non-suppurative complication following infection by *Streptococcus pyogenes*, or group A  $\beta$ -hemolytic streptococcal (GAS) in the tonsillopharynx. The ARF and RHD are still the leading causes of morbidity and mortality among young people in developing countries. When meeting a patient suspected of ARF, the most important thing is establishing a precise and accurate diagnosis before starting therapy. In 2015 the AHA published a revision of the Jones criteria for ARF, distinguishing several major criteria for low-risk and moderate to high-risk groups. Echocardiography has a significant role, especially in recognizing the presence of subclinical carditis, which is currently included in the major criteria for ARF. Primary prevention of ARF is carried out by adequately identifying and administering appropriate antibiotics for GAS tonsillopharyngitis. Secondary prevention is essential because it is the most effective way to prevent ARF recurrence, which can exacerbate RHD.

### REFERENCE

- Al-Jazairi, A., Al-Jaser, R., Al-Halees, Z., Shahid, M., Al-Jufan, M., Al-Mayouf, S., Al-Rajhi, A., & Al-Hajjar, S. (2017). Guidelines for the secondary prevention of rheumatic heart disease. *International Journal of Pediatrics & Adolescent Medicine*, 4(1), 47–50. <https://doi.org/10.1016/j.ijpam.2017.02.002>
- Arabaci, Ç., & Ak, K. (2020). Beta hemolytic Streptococci strains isolated from clinical specimens, their characteristics and antibiotic susceptibility. *Journal of Surgery and Medicine*. <https://doi.org/10.28982/josam.672119>
- Arafuri, N., Murni, I. K., Julia, M., Nugroho, S., & Soehadi, N. (2022). Survival of Rheumatic Heart Disease in Indonesian Children. *Global Heart*, 17(1), 71. <https://doi.org/10.5334/gh.1160>
- Auala, T., Zavale, B. G., Mbakwem, A. Ç., & Mocumbi, A. O. (2022). Acute Rheumatic Fever and Rheumatic Heart Disease: Highlighting the Role of Group A Streptococcus in the Global Burden of Cardiovascular Disease. *Pathogens*, 11(5), Article 5. <https://doi.org/10.3390/pathogens11050496>
- Barik, R. (2018). Secondary prophylaxis to control rheumatic heart disease in developing countries: Put into a cage if can't be killed. *Indian Heart Journal*, 70(6), 907–910. <https://doi.org/10.1016/j.ihj.2018.01.001>
- Brouwer, S., Rivera-Hernandez, T., Curren, B. F., Harbison-Price, N., De Oliveira, D. M. P., Jespersen, M. G., Davies, M. R., & Walker, M. J. (2023). Pathogenesis, epidemiology and control of Group A Streptococcus infection. *Nature Reviews Microbiology*, 21(7), Article 7. <https://doi.org/10.1038/s41579-023-00865-7>



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



- Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005). The global burden of group A streptococcal diseases. *The Lancet. Infectious Diseases*, 5(11), 685–694. [https://doi.org/10.1016/S1473-3099\(05\)70267-X](https://doi.org/10.1016/S1473-3099(05)70267-X)
- Choironi, E. A., Machfudz, S., & Wicaksono, M. B. (2022). *Challenges in Management of Pediatric Rheumatic Heart Disease in Indonesia: A Narrative Review*. 62–70. [https://doi.org/10.2991/978-94-6463-048-0\\_8](https://doi.org/10.2991/978-94-6463-048-0_8)
- Cilliers, A. M. (2006). Rheumatic fever and its management. *BMJ: British Medical Journal*, 333(7579), 1153–1156. <https://doi.org/10.1136/bmj.39031.420637.BE>
- Cunningham, M. W. (2000). Pathogenesis of Group A Streptococcal Infections. *Clinical Microbiology Reviews*, 13(3), 470–511.
- Desita, S. R., Lefi, A., Rahman, M., & Oktaviono, Y. H. (2021). Clinical Characteristics and Number of Valve Lesion in Rheumatic Heart Disease Severity. *Global Medical and Health Communication*, 9(1), 36–41. <https://doi.org/DOI: pISSN 2301-9123 | eISSN 2460-5441> Correspondence: Dr. Achmad Lefi, Sp.J.P.(K.), FIHA. Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Airlangga/Dr. Soetomo Regional General Hospital. Jln. Mayjen. Prof. Dr. Moestopo No. 47, Surabaya 60132, East Java, Indonesia. E-mail: achmad.lefi@fk.unair.ac.id Received: 31 August 2020; Revised: 11 February 2021; Accepted: 26 March 2021; Published: 30 April 2021 <https://doi.org/10.29313/gmhc.v9i1.6609>
- Gerber, M. A., Baltimore, R. S., Eaton, C. B., Gewitz, M., Rowley, A. H., Shulman, S. T., & Taubert, K. A. (2009). Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis. *Circulation*, 119(11), 1541–1551. <https://doi.org/10.1161/CIRCULATIONAHA.109.191959>
- Gewitz, M. H., Baltimore, R. S., Tani, L. Y., Sable, C. A., Shulman, S. T., Carapetis, J., Remenyi, B., Taubert, K. A., Bolger, A. F., Beerman, L., Mayosi, B. M., Beaton, A., Pandian, N. G., & Kaplan, E. L. (2015). Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. *Circulation*, 131(20), 1806–1818. <https://doi.org/10.1161/CIR.0000000000000205>
- Kaplan, E. L. (2005). Pathogenesis of acute rheumatic fever and rheumatic heart disease: Evasive after half a century of clinical, epidemiological, and laboratory investigation. *Heart*, 91(1), 3–4. <https://doi.org/10.1136/hrt.2004.034744>
- Katzenellenbogen, J. M., Ralph, A. P., Wyber, R., & Carapetis, J. R. (2017). Rheumatic heart disease: Infectious disease origin, chronic care approach. *BMC Health Services Research*, 17, 793. <https://doi.org/10.1186/s12913-017-2747-5>
- Kumar, R. K., Antunes, M. J., Beaton, A., Mirabel, M., Nkomo, V. T., Okello, E., Regmi, P. R., Reményi, B., Sliwa-Hähnle, K., Zühlke, L. J., Sable, C., & null, null. (2020). Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association. *Circulation*, 142(20), e337–e357. <https://doi.org/10.1161/CIR.0000000000000921>
- Kumar, R. K., & Tandon, R. (2013). Rheumatic fever & rheumatic heart disease: The last 50 years. *The Indian Journal of Medical Research*, 137(4), 643–658.



# QANUN MEDIKA

## JURNAL KEDOKTERAN FKUM SURABAYA

<http://journal.um-surabaya.ac.id/index.php/qanunmedika>



- Madiyono, B. (1998). Pediatric Cardiology in The Past, Present, and Future: Its Role in The Prevention and Management of Cardiovascular Disease. *Paediatrica Indonesiana*, 38(1–2), 1–19. <https://doi.org/10.14238/pi38.1-2.1998.1-19>
- Maryland, V. W., RPh Consultant Pharmacist Rockville. (2020). *Preventing Rheumatic Heart Disease*. <https://www.uspharmacist.com/article/preventing-rheumatic-heart-disease>
- Ralph, A. P., Noonan, S., Wade, V., & Currie, B. J. (2020). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. *Medical Journal of Australia*, 214(5). <https://www.mja.com.au/journal/2021/214/5/2020-australian-guideline-prevention-diagnosis-and-management-acute-rheumatic>
- Reményi, B., Wilson, N., Steer, A., Ferreira, B., Kado, J., Kumar, K., Lawrenson, J., Maguire, G., Marijon, E., Mirabel, M., Mocumbi, A. O., Mota, C., Paar, J., Saxena, A., Scheel, J., Stirling, J., Viali, S., Balekundri, V. I., Wheaton, G., ... Carapetis, J. (2012). World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—An evidence-based guideline. *Nature Reviews. Cardiology*, 9(5), 297–309. <https://doi.org/10.1038/nrcardio.2012.7>
- Rudiktyo, E., Wind, A., Doevendans, P., Siswanto, B. B., Cramer, M.-J., & Soesanto, A. M. (2022). Characteristics of patients with rheumatic heart disease in a national referral hospital in Indonesia. *Medical Journal of Indonesia*, 31(3), Article 3. <https://doi.org/10.13181/mji.oa.226150>
- Seckeler, M. D., & Hoke, T. R. (2011). The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clinical Epidemiology*, 3, 67–84. <https://doi.org/10.2147/CLEP.S12977>
- Sudeep, D. D., & Sredhar, K. (2013). The Descriptive Epidemiology of Acute Rheumatic Fever and Rheumatic Heart Disease in Low and Middle-Income Countries. *American Journal of Epidemiology and Infectious Disease*, 1(4), Article 4. <https://doi.org/10.12691/ajeid-1-4-2>
- Syam, D. R., Yosy, D. S., Bakri, A., & Nova, R. (2020). Epidemiologic profiles of subclinical rheumatic heart disease in children. *Paediatrica Indonesiana*, 60(6), 334–340. <https://doi.org/10.14238/pi60.6.2020.334-40>
- Watkins, D. A., Johnson, C. O., Colquhoun, S. M., Karthikeyan, G., Beaton, A., Bukhman, G., Forouzanfar, M. H., Longenecker, C. T., Mayosi, B. M., Mensah, G. A., Nascimento, B. R., Ribeiro, A. L. P., Sable, C. A., Steer, A. C., Naghavi, M., Mokdad, A. H., Murray, C. J. L., Vos, T., Carapetis, J. R., & Roth, G. A. (2017). Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. *New England Journal of Medicine*, 377(8), 713–722. <https://doi.org/10.1056/NEJMoa1603693>
- WHO. (2004). *Rheumatic fever and rheumatic heart disease: Report of a WHO expert consultation, Geneva, 29 October - 1 November 2001*. World Health Organization. [www.who.int/cardiovascular\\_diseases/resources/trs\\_923/en](http://www.who.int/cardiovascular_diseases/resources/trs_923/en)



WHO. (2020). *Rheumatic heart disease*. Rheumatic Heart Disease. <https://www.who.int/news-room/fact-sheets/detail/rheumatic-heart-disease>

Woldu, B., & Bloomfield, G. S. (2016). Rheumatic Heart Disease in the Twenty-First Century. *Current Cardiology Reports*, 18(10), 96. <https://doi.org/10.1007/s11886-016-0773-2>